Volume 16 Supplement 1

Proceedings of the ACM Ninth International Workshop on Data and Text Mining in Biomedical Informatics: medical informatics and decision making

Open Access

Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy

  • Yejin Kim1,
  • Yong Hyun Park2,
  • Ji Youl Lee2,
  • In Young Choi3 and
  • Hwanjo Yu1Email author
BMC Medical Informatics and Decision MakingBMC series – open, inclusive and trusted201616(Suppl 1):63

https://doi.org/10.1186/s12911-016-0297-0

Published: 18 July 2016

Abstract

Background

Prostate specific antigen (PSA) is an important biomarker to monitor the response to the treatment, but has not been fully utilized as a whole sequence. We used a longitudinal biomarker PSA to discover a new prognostic pattern that predicts castration-resistant prostate cancer (CRPC) after androgen deprivation therapy.

Methods

We transformed the longitudinal PSA into a discrete sequence, used frequent sequential pattern mining to find candidate patterns from the sequences, and selected the most predictive and informative pattern among the candidates.

Results

Patients were less likely to be CRPC if, after PSA values reach nadir, the PSA decreases more than 0.048 ng/ml during a month, and the decrease occurs again. This pattern significantly increased the accuracy of predicting CRPC by supplementing information provided by existing PSA patterns such as pretreatment PSA.

Conclusions

This result can help clinicians to stratify men by the risk of CRPC and to determine the patient that needs intensive follow-up.

Keywords

Prostate specific antigen Longitudinal biomarker Frequent sequential pattern mining Prediction

Background

Prostate cancer has been the most common cancer in men worldwide [13]; it accounted for 27 % of new cancer cases in 2014 [3]. Androgen deprivation therapy (ADT) is the primary treatment of metastatic prostate cancer. ADT is conducted by suppressing androgens by castration, inhibiting the action of androgen using competing compounds known as anti-androgens, or by combining these treatments. Unfortunately, some patients proceed to castration-resistant prostate cancer (CRPC), whereas others retain hormone-sensitive prostate cancer (HSPC). For those who will be possibly endangered to CRPC, intensive follow-up and additional systematic therapies are required. Thus clinicians must assess the risk of progression to CRPC.

Prostate specific antigen (PSA) has been an important biomarker for diagnosis and prognosis of ADT. PSA level is measured during follow-up to monitor the response to the treatment. Generally, PSA level decreases after ADT begins, reaches the lowest level (nadir), then stabilizes for some period. If the cancer develops, PSA level increases. PSA has been used in therapeutic decision making by stratifying the risk of development to CRPC [4]. Characteristics of PSA variation are summarized as patterns such as pretreatment PSA level, nadir, time to nadir, and doubling time; these patterns have clinical significances as prognostic factors to predict CRPC [510]. However, the accuracy of these patterns as predictors is still unclear. They are computed based on only one or two PSA values before or around nadir even though PSA accumulates consistently after the treatment.

Patterns generated from a fully-utilized PSA sequence may increase the accuracy of predicting CRPC. Although the latter parts of PSA accumulation reflect the progression to CRPC [4], they have been discarded for three reasons: (1) Collection of PSA data from electronic medical records has been limited [11]; (2) Computing the characteristic patterns with the whole PSA sequence is more complicated than with one or two representative values; and (3) The relationship between PSA after nadir and CRPC has not been fully quantified. However, the patterns of PSA after nadir can provide insight into this relationship.

Thus we aim to exploit longitudinal PSA data to discover a new prognostic pattern that predicts CRPC after ADT, and to demonstrate clinical significance of the new pattern. We will compare this pattern with existing patterns.

Methods

We described a framework that discovers the prognostic pattern from the longitudinal PSA. This framework consists of three parts: transformation, pattern mining, and pattern selection.

Materials

Patients. We exploited data in electronic medical records (EMRs) that include longitudinal PSA level and other clinical variables. The EMR data were from an observational longitudinal database at Seoul, St. Mary Hospital, Korea; the database has been described in detail previously [12]. Among 1068 men diagnosed from January 2006 to June 2012 at our institution, 458 were treated as ADT. We only included 370 men who had not received any other treatment such as radical prostatectomy or radiation therapy and for whom PSA level data were available.

Longitudinal PSA. Each patients had a set of longitudinal PSA values that were recorded during follow-up every one to six months. The time to nadir has been investigated as the primary time point at which the kinetics of PSA level changes [6]; thus we separated the longitudinal PSA sequences into before and after nadir. Among the total of 2883 PSA values, 1238 were before nadir and 1645 were after nadir. We excluded PSA after CRPC because we should predict CRPC before it occurs. Some patients had only before or after nadir. After separation, 261 men had PSA after nadir, and 306 men had PSA before nadir.

Other variables. Patients had 14 demographic and clinical features: Age, laboratory results of Alb, Plt, Hb, Ca; medication information on intermittent treatment, drug order; bone metastasis, clinical stage; Gleason score, MRI prostate volume, pretreatment PSA, nadir, time to nadir. Patients also had two outcome variables: dichotomous factor for CRPC occurrence, and the time to CRPC. The CRPC variables were determined after being reviewed by the single urologist (Y.H.P.). Missing values were imputed using random survival forest [13]. To provide clinical background profiles of patients, the representative characteristics of the patients that have PSA after nadir were evaluated. Existence of bone metastasis can be cause of CRPC [14], and CRPC patients are more likely to have high Gleason score [15]. The p-value of the most representative features to predict CRPC by univariate Cox regression was assessed (Table 1).
Table 1

Characteristics and p-value of patients that have PSA after nadir

 

Total

CRPC

p-value

Number of patients

261

96

-

Mean follow-up ± s.d.

38.7 ± 3.5

15.8 ± 2.4

-

Mean age ± s.d.

74 ± 0.9

75.2 ± 1.7

0.011

Mean time to nadir ± s.d.

10.3 ± 1.3

8.9 ± 1.9

0.001

Mean pretreatment PSA ± s.d.

119.4 ± 39.4

151.5 ± 80.3

0.054

Mean PSA nadir ± s.d.

12.8 ± 11.7

6.6 ± 4.2

0.142

Bone metastasis

   

Yes

41

15

0.490

No

220

79

 

Gleason score

  

0.117

≤ 6

59 (22.6 %)

20 (21.2 %)

 

7

72 (27.5 %)

21 (22.3 %)

 

≥ 8

130 (49.8 %)

53 (56.3 %)

 

ADT type

   

Leuprin only

154

44

0.012

Zoladex only

36

10

 

Leuprin → Zoladex

9

6

 

Zoladex → Leuprin

49

27

 

Anti-androgen only

13

7

 

Transformation

PSA velocity

We first converted PSA level to PSA velocity (PSAV) [ng/(ml · mo)]:
$$ PSAV = \frac{{PSA}_{t_{2}}-{PSA}_{t_{1}}}{t_{2} - t_{1}}, $$
(1)

where \({PSA}_{t_{i}}\) is PSA [ng/ml] at time t i [mo] [16]; so PSA sequence was converted into PSAV sequence, which can capture directions and the amount of PSA change. PSAV ≥0 and ≤0 referred to increasing and decreasing PSA level per month, respectively. PSAV is sometimes expressed as logarithm [17], but we did not log-transform PSA because log(P S A) change means relative change (i.e. multiple of previous PSA) rather than absolute change. We discriminated small change from large change when the ratio of two PSA values was the same. For example, PSA changes from 0.003 to 0.001 and from 30 to 10 have the same log(P S A) changes, but different PSAV.

Discretization

PSAV was abstracted using discretization methods because continuous PSAV contains noise that might reduce its generalizability. We denoted PSAV state as the discretized PSAV; so PSAV sequence was converted to PSAV state sequence. Two discretization methods were used: equal-frequency binning and entropy-based discretization. We used both methods and compared them to avoid biased discretization split-points.
  • Equal-frequency binning is an unsupervised discretization technique that splits continuous variables into a specified number of bins to have equal frequency. We set bin size to five. These PSAV states were labeled as Low (L q ), Medium low (M L q ), Medium (M q ), Medium high (M H q ), and High (H q ). This method did not distinguish PSAV of CRPC from PSAV of HSPC.

  • Entropy-based discretization is a supervised discretization technique that finds split-points with minimum entropy, and recursively partitions the intervals until a stopping criterion is met [18]. PSAV values were separated into three PSAV states, which were labeled as Low (L e ), Medium (M e ), and High (H e ). Because entropy is increased when PSAV of CRPC and PSAV of HSPC are mixed, this method generated PSAV states so that PSAV values from CRPC and HSPC belonged to distinct PSAV state as much as possible.

As an example of the transformation using after-nadir longitudinal PSA by entropy-based discretization we consider the PSA sequence (Figs. 1 and 2) from a patient treated with two medications (Zoladex and Leuprin) intermittently. PSA level reached nadir at 15 months after treatment began (Fig. 1). The PSA values were converted into PSAVs (Fig. 2), and then PSAVs were assigned to one of the PSAV states (i.e. L e , M e , H e ) that separate PSAVs by the dashed lines (Fig. 2). The interval of PSAV states is computed by entropy-based discretization. PSAV values at (,−1),[−1,6), and [6,) are discretized as L e ,M e , and H e , respectively. Consequently, the PSA sequence becomes the PSAV state sequence M e M e M e L e M e M e M e M e M e M e L e .
Fig. 1

PSA sequence. Example of transformation based on after-nadir longitudinal PSA by entropy-bases discretization

Fig. 2

PSAV sequence and PSAV state. Example of transformation based on after-nadir longitudinal PSA by entropy-bases discretization. PSA sequence (Fig. 1) was transformed to PSAV sequence (Fig. 2), then PSAV state (L e ,M e ,H e ) sequence. Dashed lines: borders between PSAV states (labeled)

Pattern mining

To fully utilize longitudinal PSA data, we split PSAV state sequence into before- and after-nadir PSAV state sequences, and investigated the whole PSAV state sequence at the same time. We then used the frequent sequential pattern mining (FSPM) method to find new prognostic patterns. This method is the most widely used method for a set of discrete sequences. This method is also more computationally advantageous for a set of short and single sequences than are other methods that were mostly devised to analyze heterogeneous and large-scale data [1922]. The PSAV state sequences were also short due to the short follow-up periods. We used FSPM to find candidate prognostic PSA patterns.

Particularly we used PrefixSpan algorithm for FSPM, which is a pattern-growth approach that builds prefix patterns that concatenate with suffix patterns to find frequent patterns [18, 23]. For examples, let assume that we have PSAV state sequences in Table 2 and minimal frequency of 0.1. We began with length-one prefix. The number of instance of length-one sequential patterns is L: 5, ML: 4, M: 6, MH: 1, H: 2. We discarded MH with frequency (=1/18) < 0.1. We then divided the search space with each prefix and searched sequential patterns starting with the prefix. We listed up the subset of PSAV state sequences starting with the prefix and discarded PSAV state sequence with frequency < 0.1. We repeated these process until the prefix becomes the whole PSA state sequence.
Table 2

Example of PrefixSpan

 

PSAV state sequences

1

LLLM HM

2

LMM LL

3

HM LMMM L

4

HMLMM LM

We restricted the patterns to have a support ≥0.3 to ensure the enough frequency, and a length ≤3 to avoid over-fitting. The discovered set of candidate patterns were the subset of PSAV state sequences. The patterns were time-ordered but not always consecutive.

Selection

Predictive pattern selection

To select the predictive patterns among the candidates set that were generated from FSPM, we evaluated the accuracy by measuring the area under the receiver-operating characteristic curve (AUC) and Harrell’s concordance index (C-index) [24]. Each candidate pattern p was used as the predictor of CRPC because, by contraposition, if HSPC patients have a pattern p, a patient without the pattern p would be CRPC, and vice versa. We used baseline set containing the 14 demographic and clinical features that were extracted from the EMRs. We added each candidate pattern p to the baseline B (i.e. Bp) to evaluate the pattern p. We evaluated the discriminative power of the pattern p using
$$ \bigtriangleup \text{AUC}=\text{AUC}(B \cup p) - \text{AUC}(B), $$
(2)
and
$$ \bigtriangleup \text{C-index} = \text{C-index}(B\cup p) - \text{C-index}(B) $$
(3)

where AUC(X) denotes AUC of a logistic regression to predict CRPC using dataset X, and C-index(X) denotes the C-index of a Cox regression to predict time to CRPC using dataset X. They represent the net increase in AUC and C-index compared to the baseline. Ten-fold cross validation was used. A paired t-test with 95 % confidence level was conducted to identify patterns that increase the AUC and C-index significantly; patterns that had p-value ≤0.05 were excluded. The remaining significantly predictive patterns among the candidate set became the final candidate set from which the last pattern was selected.

Informative pattern selection

Among the significantly predictive patterns, we chose the most informative pattern. We preferred specific and rare patterns to broad and prevalent ones if the patterns have similar accuracy, because the former pattern provides relatively more information than the latter one. We formulated the relative information as follows:

Lemma 1.

Let p 1,p 2 denote patterns that the prediction accuracy are not significantly different, and let I(p) denote the relative amount of information expressed by pattern p. Then I(p 2)≤I(p 1) if
  1. 1.

    p 2 is a sub-pattern of p 1 or

     
  2. 2.

    The interval of p 1 is a subset of interval of p 2 or

     
  3. 3.

    The frequency of p 1 is smaller than frequency of p 2.

     

Cases 1 and 2 indicate that all patients that have p 1 also have p 2; thus p 1 is more specific than p 2. For example, p 2 is the sub-pattern of p 1 if p 1=LL, p 2=L because L is a sub-pattern of LL (Case 1). When p 1=L e , p 2=L q where L e has the interval of PSAV ≤−0.048, and L q has the interval PSAV ≤−0.005, then p 1 is more specific than p 2 (Case 2). Case 3 implies that p 1 occurs more rarely than p 2. If p 1 is rare than p 2 although p 1 and p 2 have similar prediction accuracy, it means that the amount of information that p 1 carries per instance. For example, if p 1=L e , p 2=M q where the frequency of p 1 is 14.4 %, and the frequency of p 2 is 59.3 %, then p 1 is more informative than p 2 because p 1 is more rare than p 2 in spite of the same prediction accuracy. We compared the amount of information using Lemma 1, and selected from the candidate set the final prognostic pattern that has the largest amount of information.

Comparison

We compared the progression to CRPC of the final pattern with that of pretreatment PSA, nadir, and time to nadir, which are known as the prognosis factors of CRPC. We computed the log-rank statistics of Kaplan-Meier analysis to test survival difference between patients with and without the pattern. The thresholds of pretreatment, nadir, and time to nadir were 100 ng/ml, 0.2 ng/ml, and 12 months, respectively [6].

Software

We used R3.0.3 [25] with two packages: survival [26, 27] for the significance test, Cox regression and log-rank test; and randomSurvivalForest [13, 27] for the imputation. We also used JAVA API, SPMF [28] to implement FSPM.

Results

We separated the longitudinal PSA data into before and after nadir. For the after-nadir dataset, we had 261 patients (HSPC: 167, CRPC: 94), and the mean follow-up time was 38.7 ± 3.5 months; the mean time to CRPC was 15.8 ± 2.4 months. Median PSAV was 0.022 ng/(ml · mo) (from -1521 to 2091). (Analysis of the before-nadir data did not reveal any prognostic patterns (Appendix Appendix A: Results of before-nadir PSA values)).

We discretized the continuous PSAV values into five and three PSAV states by equal-frequency binning (Table 3) or entropy-based discretization (Table 4). Equal-frequency binning generated PSAV states of which frequency was evenly distributed over the five states. Entropy-based method generated three PSAV states; 85 % were M e , 14 % were L e , and 1 % were H e . M e occurred in both CRPC and HSPC, L e occurred only in HSPC, and H e occurred only in CRPC.
Table 3

Discretization to PSAV state after nadir by equal-frequency binning

PSAV state

Interval

 

Frequency [%]

Value [ng/(ml ·mo)]

L q

(0, 20]

(, −0.005]

M L q

(20, 40]

(−0.005, 0.005]

M q

(40, 60]

(0.005, 0.068]

M H q

(60, 80]

(0.068, 0.454]

H q

(80, 100]

(0.454,)

L q = Low, M L q = Medium low, M q = Medium, M H q = Medium high, H q = High

Table 4

Discretization to PSAV state after nadir by entropy-based discretization

PSAV state

Interval

 

Frequency [%]

Value [ng/(ml ·mo)]

L e

(0, 14.1]

(, −0.048]

M e

(14.1, 99.2]

(−0.048, 5.43]

H e

(99.2, 100]

(5.43,)

L e = Low, M e = Medium, H e = High

We found the candidate patterns from the set of after-nadir PSAV state sequences. Among the after-nadir 261 patients’ sequences, we found 13 HSPC and 3 CRPC frequent patterns by equal-frequency binning (Table 5); and 6 HSPC and 2 CRPC frequent patterns by entropy-based discretization (Table 6). The PSAV state sequences from CRPC were rather uncommon among them; thus we could not find many frequent patterns from CRPC. In contrast, the PSAV state sequences from HSPC contained patterns that occurred repeatedly.
Table 5

After-nadir candidate patterns by equal-frequency binning

Pattern (support)

HSPC

CRPC

L q

(0.51),

L q L q

(0.34)

M q

(0.45)

M L q

(0.54),

M q L q

(0.31)

M H q

(0.43)

M q

(0.54),

M q M q

(0.35)

H q

(0.36)

M H q

(0.54),

M H q L q

(0.40)

  

H q

(0.48),

M H q H q

(0.31)

  
  

M H q M H q

(0.36)

  
  

H q L q

(0.34)

  
  

H q H q

(0.32)

  

L q ,M L q ,M q ,M H q ,H q = PSAV state (Table 3)

Table 6

After-nadir candidate patterns by entropy-based discretization

Pattern (support)

HSPC

CRPC

L e

(0.49)

M e

(0.88)

M e

(0.95)

M e M e

(0.55)

L e L e

(0.33)

  

L e M e

(0.38)

  

M e L e

(0.49)

  

M e M e

(0.81)

  

L e ,M e = PSAV state (Table 4)

We computed the AUC and C-index when each candidate pattern was added to the baseline, and checked the significances of the AUC and C-index by calculating the p-values of paired t-tests. Five patterns from HSPC and the after-nadir were predictive in that they increased the AUC and C-index significantly (Table 7), but none of the patterns from CRPC or the before-nadir were predictive. The two equal-frequency binning patterns were observed: (1) L q : PSA decline ≥0.005 ng/ml per month after nadir, (2) L q L q : two PSA declines ≥0.005 ng/ml per month after nadir; they showed the AUC of 0.81 and C-index of 0.78 – 0.79. The two entropy-based discretization patterns with L e were observed: (1) L e : PSA decline ≥0.048 ng/ml per month after nadir, (2) L e L e : two PSA declines ≥ 0.048 ng/ml per month after nadir; they showed the AUC of 0.81 – 0.82 and C-index of 0.77 – 0.81. One entropy-based discretization pattern with M e before L e was observed; this was M e L e : PSA decline from 0.048 to 5.43 ng/ml per month followed by PSA decline ≥ 0.048 ng/ml per month after nadir; this pattern showed the AUC of 0.84 and C-index of 0.81.
Table 7

Mean and s.d. of logistic regression and Cox regression when each candidate pattern is added to baseline

Pattern

Logistic regression

Cox regression

 

Mean AUC

s.d.

Mean C-index

s.d.

Baseline

0.6951

0.0686

0.6898

0.0429

L q

0.8102

0.0549

0.7938

0.0323

L q L q

0.8110

0.0500

0.7815

0.0384

L e

0.8103

0.0665

0.8090

0.0442

L e L e

0.8245

0.0352

0.7733

0.0623

M e L e

0.8446

0.0459

0.8174

0.0411

The most informative pattern among the five predictive patterns was L e L e . Because the AUC and C-index among the predictive patterns were not significantly different, we compared the relative amount of information using Lemma 1 regardless of AUC and C-index. By Lemma 1.1,
$$ \begin{aligned} I(L_{e}) &\leq I(L_{e} \rightarrow L_{e}), \\ I(L_{e})&\leq I(M_{e} \rightarrow L_{e}), \\ I(L_{q})&\leq I(L_{q} \rightarrow L_{q}). \end{aligned} $$
(4)
We then had I(L e L e ),I(M e L e ),and I(L q L q ) after excluding patterns with small amounts of information. By Lemma 1.2,
$$ I(L_{q} \rightarrow L_{q})\leq I(L_{e} \rightarrow L_{e}). $$
(5)
Finally, we compared I(L e L e ) and I(M e L e ) by Lemma 1.3,
$$ I(M_{e} \rightarrow L_{e})\leq I(L_{e} \rightarrow L_{e}). $$
(6)

Thus the final pattern was L e L e .

We conducted a Kaplan-Meier analysis of the pattern L e L e and the other PSA patterns, and found that patients with L e L e showed slow progressions to CRPC, and that patients without L e L e showed fast progressions to CRPC (Figs. 3, 4, 5 and 6). The log-rank statistics of all PSA patterns had p-values ≤ 0.05. When compared with other PSA patterns, this pattern L e L e had comparable prognostic power.
Fig. 3

Pattern L e L e . Time vs. CRPC-free rate to measure survival difference. p≤0.001

Fig. 4

Pretreatment PSA. Time vs. CRPC-free rate to measure survival difference. p=0.003

Fig. 5

PSA nadir. Time vs. CRPC-free rate to measure survival difference. p=0.031

Fig. 6

Time to PSA nadir. Time vs. CRPC-free rate to measure survival difference. p=0.021

Discussion

The objective of this study was to exploit the longitudinal measurements of PSA to discover a new prognostic pattern that predicts CRPC. The results of this study demonstrated that ADT patient is more likely to retain HSPC if, after PSA values reach nadir, PSA level decreases more than 0.048 ng/ml during a month, then the decrease occurs again; thus two PSA declines ≥ 0.048 ng/ml per month after nadir could be the prognostic pattern. This pattern was significantly related to the survival time to CRPC.

This finding has not been described in previous research on how different forms of PSA kinetics are associated with prognosis [510]. The most representative PSA prognostic patterns are pretreatment PSA, nadir, time to nadir or doubling time. Previous studies did not investigate all available PSA values, but instead used only one or two PSA values before or around nadir; thus the predictive value of PSA change during ADT was not clearly evaluated. In contrast, our pattern was computed from the whole PSA sequence, including even the latter parts. Although the initial response to ADT has important clinical significance, the subsequent response that is inferred from PSA after nadir might also contain information that can be used to predict CRPC. Incorporating PSA level as the sequence might enable us to understand the response to ADT more specifically.

We found that the two substantial declines after PSA nadir ensured sensitivity to ADT. The concept of the two substantial declines after PSA nadir can be confusing for clinicians, because nadir PSA means the lowest PSA value around a given point of observation. The occurrence of two substantial declines after PSA nadir implies that PSA fluctuates after nadir. PSA might increase due to some reasons such as intermittent treatment, and decline as sensitively reacting to ADT. We can further infer that the main difference between HSPC and CRPC is on whether PSA level fluctuates as the response to ADT.

The importance of this study is that the PSA decline after nadir helps to stratify men by the risk of CRPC and to determine the patient population that needs intensive follow-up. Risk assessment of the disease progression to CRPC has been based on the early PSA values, (i.e. before or around nadir) and has been limited to measuring the initial response. PSA after nadir has been neglected due to the complicated nature of computation, but we demonstrated that considering the after-nadir PSA pattern significantly increased the accuracy of the risk assessment by supplementing the early risk assessment obtained using the before-nadir PSA. Thus we can easily identify high-risk men who need in-depth follow-up. Therapeutic decision-making based on appropriate risk stratification enables clinicians to use clinical resource effectively.

This study has two main limitations. The first limitation is that the PSA decline pattern may occur at any time after nadir, so clinicians must wait until the pattern occurs, which must occur after the nadir. This means that clinicians must wait a long time to check whether PSA level declines; this delay is a disadvantage because rapid risk assessment is preferable when designing therapies for high-risk patients. However, FSPM with time constraints can solve this problem [18]. The time-gap between the PSAV states in the discovered pattern can be restricted. The PSAV states that occur within a specified gap reduce the time required to detect the occurrence than PSAV states without the gap. The second limitation is that analysis of the PSA decline pattern was focused on predicting HSPC. The median time to CRPC was only 15.8 months, whereas the median follow-up of all population was 38.7 months. The PSAV sequence from CRPC was not long enough to discover meaningful patterns, so most frequent patters were from HSPC. We predicted CRPC indirectly by predicting HSPC using the PSA decline pattern. A prognostic pattern that occurs frequently in CRPC can help detect CRPC directly, and this prognostic pattern from CRPC can be discovered if the quantity of data is increased and the follow-up time is extended.

Conclusions

This study discovered a prognostic PSA pattern that predicts CRPC for ADT using FSPM, and demonstrated the clinical significance of the pattern. A patient in which PSA declined twice by ≥ 0.048 ng/ml per month after nadir was predicted to retain HSPC, and a patient in which these declines did not occur was predicted to develop CRPC; the prediction had the AUC of 0.82 if the pattern was combined with pretreatment PSA, nadir, and time to nadir. These results can help risk stratification of ADT patients.

Appendix A: Results of before-nadir PSA values

For the before-nadir dataset, we had 306 patients (HSPC: 233, CRPC: 73), and the mean follow-up time was 37.7 ± 3.5 months; the mean time to CRPC was 17.5 ± 0.3 months. Median PSAV was -0.12 ng/(ml · mo) (from -1917 to 1686). After discretization, equal-frequency binning gave five discrete PSAV states (Table 8); but the entropy-based discretization could not be applied because the PSAV distributions of CRPC and HSPC were too similar. Among the 306 patients’ PSAV state sequences, we discovered 6 HSPC and 5 CRPC frequent patterns from equal-frequency binning (Table 9). We computed the AUC and C-index when each frequent pattern is added to the baseline, but we could not find patterns that increase AUC and C-index significantly.
Table 8

Discretization to PSAV state before nadir by equal-frequency binning

PSAV state

Interval

 

Frequency [%]

Value [ng/(ml ·mo)]

L bq

(0, 20]

(, −5.567]

M L bq

(20, 40]

(−5.567, −0.611]

M bq

(40, 60]

(−0.611, −0.026]

M H bq

(60, 80]

(−0.026, 0.005]

H bq

(80, 100]

(0.005,)

L bq = Low, M L bq = Medium low, M bq = Medium, M H bq = Medium high, H bq = High

Table 9

Before-nadir candidate patterns by equal-frequency binning

Pattern (support)

HSPC

CRPC

L bq

(0.78)

L bq

(0.64)

M L bq

(0.52)

M L bq

(0.61)

M bq

(0.41)

M bq

(0.52)

M H bq

(0.36)

L bq M bq

(0.31)

H bq

(0.37)

M L bq M bq

(0.33)

L bq M L bq

(0.33)

  

L bq ,M L bq ,M bq ,M H bq ,H bq = PSAV state (Table 8)

Notes

Declarations

Availability of data and materials

Not available.

Authors’ contributions

The first author YK contributed the majority of the writing and conducted major parts of the experiments. YHK contributed writing on discussion and provided important insights and clinical suggestions. JYL and IYC provided the motivation of this work and helpful comments on both method and discussion. HY provided helpful comments on method and presentation with detailed edits. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved and performed in accordance with the approved guidelines by the Institutional Review Board at the Catholic University of Korea, Seoul St. Mary’s Hospital (IRB number: KC15EISI0103).

Declarations

Publication charges for this work was partly supported by the Ministry of Science, ICT and Future Planning NIPA-2014-H0201-14-1001 ”IT Consilience Creative Program”, the ICT R&D program of MSIP/IITP B0101-15-0307 "Basic Software Research in Human-level Lifelong Machine Learning", and the Ministry of Education, Science and Technology No. 2012M3C4A7033344 "Next-Generation Information Computing Development Program through the National Research Foundation of Korea". This article has been published as part of BMC Medical Informatics and Decision Making Volume 16 Supplement 1, 2016: Proceedings of the ACM Ninth International Workshop on Data and Text Mining in Biomedical Informatics. The full contents of the supplement are available online at https://bmcmedinformdecismak.biomedcentral.com/articles/supplements/volume-16-supplement-1.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Creative IT Engineering, POSTECH
(2)
Department of Urology, Seoul St. Mary’s Hospital
(3)
Department of Medical Informatics, The Catholic University of Korea College of Medicine

References

  1. Boyle P, Ferlay J. Cancer incidence and mortality in europe, 2004. Ann Oncol. 2005; 16(3):481–8.View ArticlePubMedGoogle Scholar
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: Cancer J Clinic. 2008; 58(2):71–96.Google Scholar
  3. Siegel R, Ma JM, Zou ZH, Jemal A. Cancer statistics, 2014. Ca-a Cancer J Clinic. 2014; 64(1):9–29. doi:10.3322/Caac.21208.View ArticleGoogle Scholar
  4. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G. Eligibility and response guidelines for phase ii clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol. 1999; 17(11):3461–7.PubMedGoogle Scholar
  5. Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol. 2009; 181(6):2520–5.View ArticlePubMedGoogle Scholar
  6. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol. 2002; 168(3):995–1000.View ArticlePubMedGoogle Scholar
  7. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer. 2004; 108(6):877–81.View ArticlePubMedGoogle Scholar
  8. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (int-0162). J Clinical Oncol. 2006; 24(24):3984–90.View ArticleGoogle Scholar
  9. D’Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH. Time to an undetectable prostate-specific antigen (psa) after androgen suppression therapy for postoperative or postradiation psa recurrence and prostate cancer-specific mortality. Cancer. 2007; 109(7):1290–5.View ArticlePubMedGoogle Scholar
  10. Choueiri TK, Xie W, D’Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009; 115(5):981–7.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Hillestad R, Bigelow J, Bower A, Girosi F, Meili R, Scoville R, Taylor R. Can electronic medical record systems transform health care? potential health benefits, savings, and costs. Health Affairs. 2005; 24(5):1103–17.View ArticlePubMedGoogle Scholar
  12. Choi I, Choi R, Lee J, Choi BG. Implementation of single source based hospital information system for the catholic medical center affiliated hospitals. Healthcare Inform Res. 2010; 16(2):133–9.View ArticleGoogle Scholar
  13. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat. 2008; 2(3):841–60. doi:10.1214/08-aoas169.View ArticleGoogle Scholar
  14. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68(11):4447–54.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Gu Z, Thomas G, Yamashiro J, Shintaku I, Dorey F, Raitano A, Witte O, Said J, Loda M, Reiter R. Prostate stem cell antigen (psca) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000; 19(10):1288–96.View ArticlePubMedGoogle Scholar
  16. Partin AW, Pound CR, Pearson JD, Clemens JQ, Landis PK, Epstein JI, Carter HB, Walsh PC. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43(5):649–59.View ArticlePubMedGoogle Scholar
  17. Patel A, Dorey F, Franklin J. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997; 158(4):1441–5.View ArticlePubMedGoogle Scholar
  18. Han J, Kamber M, Pei J. Data mining: concepts and techniques: Elsevier; 2011.Google Scholar
  19. Moskovitch R, Shahar Y. Medical temporal-knowledge discovery via temporal abstraction. In: AMIA Annual Symposium Proceedings, vol. 2009. San Francisco: American Medical Informatics Association: 2009. p. 452.Google Scholar
  20. Batal I, Sacchi L, Bellazzi R, Hauskrecht M. A temporal abstraction framework for classifying clinical temporal data. In: AMIA Annual Symposium Proceedings, vol. 2009. San Francisco: American Medical Informatics Association: 2009. p. 29.Google Scholar
  21. Hripcsak G, Albers DJ, Perotte A. Exploiting time in electronic health record correlations. J Am Med Inform Assoc. 2011; 18(Supplement 1):109–15.View ArticleGoogle Scholar
  22. Hanauer DA, Ramakrishnan N. Modeling temporal relationships in large scale clinical associations. J Am Med Informatics Assoc. 2013; 20(2):332–41.View ArticleGoogle Scholar
  23. Pei J, Han J, Mortazavi-Asl B, Wang J, Pinto H, Chen Q, Dayal U, Hsu MC. Mining sequential patterns by pattern-growth: The prefixspan approach. Knowl Data Eng IEEE Trans. 2004; 16(11):1424–40.View ArticleGoogle Scholar
  24. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. Jama. 1982; 247(18):2543–6.View ArticlePubMedGoogle Scholar
  25. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing. R Foundation for Statistical Computing. 2014. https://www.r-project.org/.
  26. T T. A Package for Survival Analysis in S. 2014. http://CRAN.R-project.org/package=survival. Accessed 15 Jan 2015.
  27. Terry M. Therneau PMG. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.View ArticleGoogle Scholar
  28. Viger PF, Gomariz A, Gueniche T, Soltani A, Wu CW, Tseng VS. Spmf: A java open-source pattern mining library. J Mach Learn Res. 2014; 15:3389–93.Google Scholar

Copyright

© Kim et al. 2016